



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: June 27, 2008

To: Primary Clinical Research Associates

From: Jacqueline M. Lafky
NCCTG Biospecimen Resource Manager

Re: N0626, Phase II Randomized Study Pemetrexed With Sorafenib versus Pemetrexed Alone as Second-line Therapy in Patients With Advanced Non-Small Cell Lung Cancer

As of Addendum 3, the pharmacokinetic blood draws are no longer required. The research blood collection kits and instructions have been modified to reflect this change. Please replace any existing kits you may have in stock by faxing the MCLCT fax supply order form (found in the forms packet) to the number listed on the form.

If you have any questions, please feel free to contact me at 507/538-0602.

Enclosure